✦ LIBER ✦

Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma

✍ Scribed by Manish S. Bhandari; Kenneth J. Pienta; Judith Fardig; Karin Olson; David C. Smith

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 90 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21815

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of epirubicin, cisplatin,

Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma

✍ Yoon T. Jeen; So Y. Yoon; Sang W. Shin; Byung S. Kim; Young J. Mok; Chong S. Kim 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 3 views

A phase II trial of oral tegafur and ura

A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer

✍ Yukito Ichinose; Nobuko Takanashi; Tokujiro Yano; Hiroshi Asoh; Hideki Yokoyama; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 2 views

## Background: The combination of uracil and tegafur in a 4:1 molar concentration (uft) has a greater antitumor activity than 5-fluorouracil (5-fu) and tegafur. because the combination of 5-fu and cisplatin has been proven to have a synergistic antitumor effect in many experimental and clinical stu

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi

Phase II study of the oral cyclophospham

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

✍ Catherine Maulard-Durdux; Bertrand Dufour; Christophe Hennequin; Y. Chrétien; Sy 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

## BACKGROUND. Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (vp-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tum

Treatment of patients with advanced gast

Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin: A phase II study of the ONCOPAZ Cooperative Group

✍ J. Feliu; M. González Barón; C. García-Girón; E. Espinosa; P. García-Alfonso; J. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 562 KB

## Background: Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-fu) have achieved promising results in patients with gastric carcinoma. conversely, several studies on gastric carcinoma have demonstrated that the combination of etoposide (vp-16), leucovorin (lv)

Phase II trial of paclitaxel, estramusti

Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma

✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t